✉news ScienceScience first seen 12 h ago, last 8 h ago, peak #32
PEACE-1 Trial Shows Long-Term Survival Benefit With Abiraterone
Original: Katy Beckermann։ PEACE-1 Trial Shows Long-Term Survival Benefit With Abiraterone in De Novo mCSPC
Dr. Katy Beckermann highlighted findings from the PEACE-1 trial showing that adding abiraterone to standard therapy provides a long-term survival benefit for men with de novo metastatic castration-sensitive prostate cancer. The update, reported by oncology news outlet Oncodaily, underscores growing evidence supporting intensified upfront treatment in this patient group, and is drawing attention among cancer specialists tracking evolving treatment standards.
Why now: New analysis from a major prostate cancer trial is informing current treatment practice.
Katy BeckermannPEACE-1 trialabiraterone
Evidence
- Katy Beckermann։ PEACE-1 Trial Shows Long-Term Survival Benefit With Abiraterone in De Novo mCSPC · Oncodaily
API: https://socialmediatrends-api.osmike.com/v1/trends/3556109